Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Talvey talquetamab patent expiration date?

See the DrugPatentWatch profile for Talvey

When does the Talvey (talquetamab) patent expire?

The exact patent expiration date for Talvey (talquetamab) depends on which specific patent(s) cover the product in each country (for example, the active ingredient, formulation, dosing regimen, and related “method of use” claims), plus any extensions or exclusivity rules that apply in that jurisdiction. Patent schedules are therefore not a single universal date.

What kinds of dates should you check besides the “patent expiry”?

For medicines like Talvey, the date a competitor can market a similar product may be later than the earliest patent expiration because regulators and courts can recognize additional protections such as:
- Patent term extensions tied to regulatory approval timing
- Data exclusivity / market exclusivity periods (rules vary by country)
- Pending or new patent litigation that can delay launch even after one patent expires

To determine the real “can rivals enter?” timeline, you normally need the combination of patent expiry plus any relevant exclusivity and legal stay details.

Which jurisdiction’s expiration date do you mean?

Patent expiration dates differ by jurisdiction. The most commonly looked-up timelines are:
- U.S. (patent term, possible patent term adjustments, and any listed Orange Book patents)
- EU/UK (patent coverage by country plus any regulatory protection mechanisms)
- Other countries (different patent filing/claim dates and enforcement)

If you tell me which country (e.g., U.S. vs EU) you care about, I can narrow the search-intent to the right type of registry record and the most relevant listed patents.

How can you quickly find the Talvey patent expiry date that matters for competitors?

The usual fastest path is to identify the patents listed for Talvey in the country’s regulatory listings, then read each patent’s scheduled expiration. For the U.S., this is commonly done via the FDA’s patent listing system (Orange Book). Other regions use similar authority registries or national patent databases.

If you share one detail, I can give a precise date

If you share either:
1) the country (U.S., EU, UK, etc.), or
2) a patent number or the listed “expiration” field you saw,

then I can translate that into the expected Talvey talquetamab patent expiration timeline for that specific scope.

Sources
None provided in your message.



Other Questions About Talvey :

Is Talvey for Myeloma? What are the side effects of Talvey?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated content accurately reflects the TALVEY label warning that TALVEY can cause cytokine release syndrome (including life-threatening/fatal reactions) and neurologic toxicity including ICANS (including serious/life-threatening/fatal reactions), and correctly links these risks to the REMS rationale.


Category Scores

Warnings
100
Excellent

Accurate Statements

TALVEY can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions.
Label section 5.1 Cytokine Release Syndrome (CRS): “TALVEY can cause cytokine release syndrome, including life-threatening or fatal reactions.”
TALVEY can cause serious, life-threatening, or fatal neurologic toxicity, including ICANS.
Label section 5.2 Neurologic Toxicity including ICANS: “TALVEY can cause serious, life-threatening, or fatal neurologic toxicity, including ICANS.”
The REMS rationale cites risks of CRS and neurologic toxicity, including ICANS.
Label section 5.3 TECVAYLI and TALVEY REMS: “REMS called the TECVAYLI and TALVEY REMS because of the risks of CRS and neurologic toxicity, including ICANS.”

Unsupported Statements


Contradictions


Important Omissions

No mention of CRS/ICANS monitoring, step-up dosing initiation, hospitalization timing, or withhold/permanent discontinue actions described in the label.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The content evaluated is limited to warning-category risk statements that are directly supported by the label; it does not omit critical management steps within the scope of the narrow claim being assessed, though additional label actions exist.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
The response focuses on the existence and severity of CRS/neurologic toxicity but does not include label-specific management instructions (e.g., step-up dosing, monitoring, withhold/discontinue actions, hospitalization requirements).

Suggested Improvement
When expanding beyond the boxed/warning-style claim, add label-supported management elements from Dosage and Administration (2.2, 2.3, 2.5) and Warnings and Precautions (5.1, 5.2).

Drug Brand Mention Assessment

Branding Score
27
Visibility
30
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • The exact patent expiration date for Talvey depends on which specific patent(s) cover the product in each country.
  • Patent schedules are not a single universal date.
Differentiators
  • Expiration depends on the specific patents covering the product in each country.
  • Timing can be affected by extensions or exclusivity rules in the jurisdiction.
  • You need a combination of patent expiry plus relevant exclusivity and legal stay details.

Pricing Perception: Not Mentioned